Core Viewpoint - BioRestorative Therapies, Inc. has successfully closed a public offering of 14,285,715 shares of common stock and warrants, raising approximately $5.0 million to fund clinical trials and development initiatives [1][3]. Group 1: Offering Details - The public offering price was set at $0.35 per share, with warrants having the same exercise price and an expiration of five years from issuance [1]. - Rodman & Renshaw LLC served as the exclusive placement agent for the offering [2]. - The offering was registered with the SEC, and a final prospectus has been filed [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to clinical trials for BRTX-100, pre-clinical research for the ThermoStem Program, development of a commercial biocosmeceuticals platform, and general corporate purposes [3]. Group 3: Company Overview - BioRestorative focuses on regenerative medicine, particularly stem cell-based therapies, with key programs targeting disc/spine diseases and metabolic disorders [6]. - The lead therapy candidate, BRTX-100, is designed for non-surgical treatment of lumbosacral disc disorders and is currently in Phase 2 clinical trials [6]. - The ThermoStem Program aims to develop therapies for obesity and metabolic disorders using brown adipose-derived stem cells [7]. - The company also operates a BioCosmeceutical platform, offering products aimed at cosmetic improvements [8][9].

Company Overview - Lexeo Therapeutics is a cardiac genetic medicines company focused on utilizing AAV gene therapy to address genetic cardiovascular diseases with high unmet needs [2] - The company's most advanced program targets Friedreich's ataxia, showing significant impacts on both cardiac and neurologic aspects of the disease [2] Treatment Efficacy - The gene therapy has resulted in all patients with abnormal heart mass returning to the normal range, indicating a positive effect on cardiac pathology [2] - Improvement in neurologic disease symptoms has been observed, with effect sizes on neurologic scales comparable to those of commercially approved therapies [2] Future Developments - Lexeo Therapeutics plans to move its Friedreich's ataxia program into a registrational study within the year, aiming to establish a new standard of care for this high unmet need disease [3]

WASHINGTON, D.C. 20549 As filed with the Securities and Exchange Commission on February 13, 2026. Registration No. 333-293204 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Amendment No. 1 THE SECURITIES ACT OF 1933 Generate Biomedicines, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 83-1630228 (Primary Standard Industrial Classification Code Number) 101 South Street, Suite 900 Somerville, MA 02143 (I.R.S. Employer ...

Core Insights - MRNA has experienced a pullback to a low of $36.66, indicating a potential successful test of support near the rising 10-week moving average at $37.74, suggesting readiness for a bullish trend continuation [1] - The key resistance level is identified at $55.20, where multiple indicators converge, and breaking this level could lead to accelerated bullish momentum [2] - Long-term upside targets for MRNA include the 200-week moving average at $92.99, with an initial target potentially being the 38.2% Fibonacci retracement at $76.72 [3] Group 1 - MRNA fell to a low of $36.66 this week, indicating a successful test of support near the 10-week moving average at $37.74 [1] - The area around $55.20 is identified as a key resistance level, with several technical indicators reinforcing this [2] - The 200-week moving average at $92.99 is highlighted as a long-term upside target, with the potential for MRNA to reach the top side of the falling channel [3] Group 2 - The bullish reaction following the low suggests that the pullback may complete the first phase after a long-term breakout [1] - The confluence of indicators at $55.20 suggests that breaking this level could confirm a continuation breakout [2] - The analysis indicates that the 38.2% Fibonacci retracement at $76.72 may be reached before the 200-week moving average [3]

Moderna Reports a Narrower-Than-Expected Loss. The Stock Slips After Earnings. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Moderna Is Losing Less Money Than Expected. The Stock Jumps After Earnings.By [Nate Wolf]ShareResize---ReprintsIn ...

Company Overview - Olema is focused on transforming the standard of care for patients with ER-positive, HER2-negative breast cancer, which represents a significant unmet medical need [2] - Breast cancer is the most common cancer diagnosis in women globally and the second leading cause of cancer death, with ER-positive, HER2-negative breast cancer accounting for 70% of cases [2] Lead Program - The lead program of Olema is palazestrant, a complete estrogen receptor antagonist, which serves as the backbone therapy for ER-positive HER2-negative breast cancer [3] - Endocrine therapy is administered in every line of treatment until chemotherapy is necessary, with the goal of delaying chemotherapy as long as possible [3] Clinical Trials - Palazestrant is currently in two Phase III trials: one as a monotherapy in the second and third-line setting, with results expected in the fall, and another in combination with ribociclib in the first-line setting [4]

Core Insights - Moderna reported fourth-quarter results that exceeded expectations, with shares rising more than 8% intra-day on Friday [1] - The company posted a quarterly loss of $2.11 per share, narrower than analyst estimates of a $2.62 loss, and revenue reached $678 million, down 30% year over year [1] - For full-year 2025, Moderna generated revenue of $1.9 billion, representing a 40% decline from 2024, with a net loss of $2.8 billion or $7.26 per share [2] Financial Performance - Fourth-quarter revenue was $678 million, modestly above the consensus forecast of $662.84 million [1] - Full-year 2025 revenue was $1.9 billion, a 40% decline from 2024 [2] - Cash and investments totaled $8.1 billion at year-end 2025, down from $9.5 billion at the end of 2024 [2] Future Outlook - Moderna reaffirmed its goal of achieving up to 10% revenue growth in 2026, with approximately half expected from U.S. markets and half from international markets [3] - The company expects research and development expenses of approximately $3.0 billion and selling, general, and administrative expenses of about $1.0 billion for 2026 [4] - Year-end cash and investments for 2026 are projected to range between $5.5 billion and $6.0 billion [4] Pipeline Developments - Moderna reported full enrollment in its Phase 3 Norovirus trial, with data anticipated in 2026 [4] - The company also achieved full enrollment in its Phase 2 intismeran autogene study for muscle invasive bladder cancer [4] - The influenza vaccine filing has been accepted for regulatory review in the European Union, Canada, and Australia, but received a Refusal-to-File letter from the U.S. FDA [3]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Insights - The company achieved a significant financial turning point in 2025 by reducing operating expenses by $2.2 billion, exceeding original cost-reduction targets by over $1 billion [1] - Revenue performance in 2025 was attributed to the successful U.S. launch of MNEXT Spike, which captured 24% of the total retail market despite a decline in overall COVID demand [1] - The company expressed strong disappointment with the FDA's Refusal to File letter for the mRNA-1010 flu vaccine, citing unpredictable regulatory environments as a threat to U.S. innovation leadership [1] Strategic Focus - The company shifted its strategic focus toward long-term sovereign partnerships in the U.K., Canada, and Australia to provide stable, annualized revenue streams starting in 2026 [1] - The oncology narrative was advanced by completing enrollment in three late-stage INT studies (melanoma, renal cell, and bladder cancer), reinforcing the platform's multi-histology potential [1] Operational Efficiency - The company leveraged AI integration across the business to drive productivity while maintaining a disciplined $1.0 billion SG&A spend and expanding into new geographic markets [1]

Core Insights - Nektar Therapeutics has successfully closed a public offering of $460 million, which includes the full exercise of underwriters' option to purchase additional shares [1] Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing innovative medicines in immunotherapy [1] - The company's lead product candidate is rezpegaldesleukin (REZPEG or NKTR-358), which is being evaluated in multiple Phase 2 clinical trials for atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus [1] - Nektar's pipeline includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422 [1] - The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist, in several ongoing clinical trials aimed at enhancing the immune system's ability to combat cancer [1] Offering Details - The offering consisted of 7,637,931 shares of common stock sold at a public offering price of $58.00 per share, along with 293,103 pre-funded warrants sold at $57.9999 each [1] - Gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions [1] - Jefferies, TD Cowen, and Piper Sandler acted as joint bookrunning managers for the offering, with Oppenheimer & Co. and H.C. Wainwright & Co. as lead managers [1]